Parvifloron D-based potential therapy for glioblastoma: Inducing apoptosis via the mitochondria dependent pathway
- Publication type:
- Journal article
- Metadata:
-
- Autoren
- Mariana Magalhaes
- Eva Maria Dominguez-Martin
- Joana Jorge
- Ana Cristina Goncalves
- Ana Maria Diaz-Lanza
- Bruno Manadas
- Thomas Efferth
- Patricia Rijo
- Celia Cabral
- Autoren-URL
- https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000876721500001&DestLinkType=FullRecord&DestApp=WOS_CPL
- DOI
- 10.3389/fphar.2022.1006832
- eISSN
- 1663-9812
- Externe Identifier
- Clarivate Analytics Document Solution ID: 5U7KI
- PubMed Identifier: 36313298
- Zeitschrift
- FRONTIERS IN PHARMACOLOGY
- Schlüsselwörter
- glioblastoma
- Plectranthus spp.
- abietane diterpenes
- antitumor activity
- molecular mechanisms
- Artikelnummer
- ARTN 1006832
- Datum der Veröffentlichung
- 2022
- Status
- Published
- Titel
- Parvifloron D-based potential therapy for glioblastoma: Inducing apoptosis <i>via</i> the mitochondria dependent pathway
- Sub types
- Article
- Ausgabe der Zeitschrift
- 13
Data source: Web of Science (Lite)
- Other metadata sources:
-
- Abstract
- <jats:p>Glioblastoma (GB) is the most malignant and frequent primary tumor of the central nervous system. The lack of diagnostic tools and the poor prognosis associated with this tumor type leads to restricted and limited options of treatment, namely surgical resection and radio-chemotherapy. However, despite these treatments, in almost all cases, patients experience relapse, leading to survival rates shorter than 5 years (∼15–18 months after diagnosis). Novel therapeutic approaches are urgently required (either by discovering new medicines or by repurposing drugs) to surpass the limitations of conventional treatments and improve patients’ survival rate and quality of life. In the present work, we investigated the antitumor potential of parvifloron D (ParvD), a drug lead of natural origin, in a GB cell line panel. This natural drug lead induced G2/M cell cycle arrest and apoptosis <jats:italic>via</jats:italic> activation of the intrinsic mitochondria-dependent pathway. Moreover, the necessary doses of ParvD to induce pronounced inhibitory effects were substantially lower than that of temozolomide (TMZ, first-line treatment) required to promote comparable effects. Therefore, ParvD may have the potential to overcome the resistance related to TMZ and contribute to the pursuit of hopeful treatments based on ParvD as a drug lead for future chemotherapeutics.</jats:p>
- Autoren
- Mariana Magalhães
- Eva María Domínguez-Martín
- Joana Jorge
- Ana Cristina Gonçalves
- Ana María Díaz-Lanza
- Bruno Manadas
- Thomas Efferth
- Patrícia Rijo
- Célia Cabral
- DOI
- 10.3389/fphar.2022.1006832
- eISSN
- 1663-9812
- Zeitschrift
- Frontiers in Pharmacology
- Online publication date
- 2022
- Status
- Published online
- Herausgeber
- Frontiers Media SA
- Herausgeber URL
- http://dx.doi.org/10.3389/fphar.2022.1006832
- Datum der Datenerfassung
- 2022
- Titel
- Parvifloron D-based potential therapy for glioblastoma: Inducing apoptosis via the mitochondria dependent pathway
- Ausgabe der Zeitschrift
- 13
Data source: Crossref
- Abstract
- Glioblastoma (GB) is the most malignant and frequent primary tumor of the central nervous system. The lack of diagnostic tools and the poor prognosis associated with this tumor type leads to restricted and limited options of treatment, namely surgical resection and radio-chemotherapy. However, despite these treatments, in almost all cases, patients experience relapse, leading to survival rates shorter than 5 years (∼15-18 months after diagnosis). Novel therapeutic approaches are urgently required (either by discovering new medicines or by repurposing drugs) to surpass the limitations of conventional treatments and improve patients' survival rate and quality of life. In the present work, we investigated the antitumor potential of parvifloron D (ParvD), a drug lead of natural origin, in a GB cell line panel. This natural drug lead induced G2/M cell cycle arrest and apoptosis <i>via</i> activation of the intrinsic mitochondria-dependent pathway. Moreover, the necessary doses of ParvD to induce pronounced inhibitory effects were substantially lower than that of temozolomide (TMZ, first-line treatment) required to promote comparable effects. Therefore, ParvD may have the potential to overcome the resistance related to TMZ and contribute to the pursuit of hopeful treatments based on ParvD as a drug lead for future chemotherapeutics.
- Addresses
- PhD Programme in Experimental Biology and Biomedicine, Institute for Interdisciplinary Research (IIIUC), University of Coimbra, Coimbra, Portugal.
- Autoren
- Mariana Magalhães
- Eva María Domínguez-Martín
- Joana Jorge
- Ana Cristina Gonçalves
- Ana María Díaz-Lanza
- Bruno Manadas
- Thomas Efferth
- Patrícia Rijo
- Célia Cabral
- DOI
- 10.3389/fphar.2022.1006832
- eISSN
- 1663-9812
- Externe Identifier
- PubMed Identifier: 36313298
- PubMed Central ID: PMC9605735
- Funding acknowledgements
- Fundação para a Ciência e a Tecnologia:
- Open access
- true
- ISSN
- 1663-9812
- Zeitschrift
- Frontiers in pharmacology
- Sprache
- eng
- Medium
- Electronic-eCollection
- Online publication date
- 2022
- Open access status
- Open Access
- Paginierung
- 1006832
- Datum der Veröffentlichung
- 2022
- Status
- Published
- Publisher licence
- CC BY
- Datum der Datenerfassung
- 2022
- Titel
- Parvifloron D-based potential therapy for glioblastoma: Inducing apoptosis <i>via</i> the mitochondria dependent pathway.
- Sub types
- research-article
- Journal Article
- Ausgabe der Zeitschrift
- 13
Files
https://www.frontiersin.org/articles/10.3389/fphar.2022.1006832/pdf https://europepmc.org/articles/PMC9605735?pdf=render
Data source: Europe PubMed Central
- Abstract
- Glioblastoma (GB) is the most malignant and frequent primary tumor of the central nervous system. The lack of diagnostic tools and the poor prognosis associated with this tumor type leads to restricted and limited options of treatment, namely surgical resection and radio-chemotherapy. However, despite these treatments, in almost all cases, patients experience relapse, leading to survival rates shorter than 5 years (∼15-18 months after diagnosis). Novel therapeutic approaches are urgently required (either by discovering new medicines or by repurposing drugs) to surpass the limitations of conventional treatments and improve patients' survival rate and quality of life. In the present work, we investigated the antitumor potential of parvifloron D (ParvD), a drug lead of natural origin, in a GB cell line panel. This natural drug lead induced G2/M cell cycle arrest and apoptosis via activation of the intrinsic mitochondria-dependent pathway. Moreover, the necessary doses of ParvD to induce pronounced inhibitory effects were substantially lower than that of temozolomide (TMZ, first-line treatment) required to promote comparable effects. Therefore, ParvD may have the potential to overcome the resistance related to TMZ and contribute to the pursuit of hopeful treatments based on ParvD as a drug lead for future chemotherapeutics.
- Date of acceptance
- 2022
- Autoren
- Mariana Magalhães
- Eva María Domínguez-Martín
- Joana Jorge
- Ana Cristina Gonçalves
- Ana María Díaz-Lanza
- Bruno Manadas
- Thomas Efferth
- Patrícia Rijo
- Célia Cabral
- Autoren-URL
- https://www.ncbi.nlm.nih.gov/pubmed/36313298
- DOI
- 10.3389/fphar.2022.1006832
- Externe Identifier
- PubMed Central ID: PMC9605735
- ISSN
- 1663-9812
- Zeitschrift
- Front Pharmacol
- Schlüsselwörter
- Plectranthus spp.
- abietane diterpenes
- antitumor activity
- glioblastoma
- molecular mechanisms
- Sprache
- eng
- Country
- Switzerland
- Paginierung
- 1006832
- PII
- 1006832
- Datum der Veröffentlichung
- 2022
- Status
- Published online
- Titel
- Parvifloron D-based potential therapy for glioblastoma: Inducing apoptosis via the mitochondria dependent pathway.
- Sub types
- Journal Article
- Ausgabe der Zeitschrift
- 13
Data source: PubMed
- Beziehungen:
- Property of